{"product_id":"bayer-business-model-canvas","title":"Bayer Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer Business Model Canvas: A Clear View of Growth, Innovation \u0026amp; Value Creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Bayer's business model-this focused Business Model Canvas shows how the company creates value across healthcare and agriculture, aligns innovation with customer needs, and supports long-term performance through R\u0026amp;D, partnerships, and diversified revenue streams; a practical starting point for understanding Bayer's market position and business structure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic R\u0026amp;D Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer runs strategic R\u0026amp;D collaborations with universities and biotech firms to share drug-discovery and agri-tech risks, co-funding projects that cut upfront costs-Bayer reported ~€1.8bn in external R\u0026amp;D investments and partnerships in 2024. By late 2025 Bayer pivoted more capital toward cell and gene therapy and next-gen biologicals, citing a 35% increase in alliance deal volume year-over-year and several co-funded trials entering Phase II.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer depends on a global network of 1,200+ logistics and wholesale partners to distribute medicines and crop inputs across 90+ countries; in 2024 this network moved products generating €44.1bn in pharma and crop science revenues, ensuring delivery to pharmacies and 25m+ farm customers. Strengthening these ties is crucial to sustain market share in emerging economies and remote regions where last-mile costs can add 8-15% to distribution spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Farming and AgTech Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with tech providers and data analytics firms power Bayer's Climate FieldView and precision farming, integrating satellite imagery, soil sensors, and AI to deliver field-level insights; by 2024 FieldView covered ~95 million hectares globally and helped users increase yields by up to 6% in pilot studies. These alliances cut inputs and emissions-partner data show up to 12% fertilizer reduction-so farmers boost productivity while lowering environmental footprints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer partners with hospitals, insurers and national health services to secure reimbursement and patient access for specialty medicines, using real-world evidence to demonstrate value; in 2024 Bayer Pharmaceuticals reported core EPS contributing to a €49.0bn Group sales run-rate, strengthening payer negotiations.\u003c\/p\u003e\n\u003cp\u003eIn 2025 these ties shift toward value-based care and integrated pathways, with pilots linking outcomes to payments-Bayer cites outcome-based contracts in oncology and rare disease pilots covering ~5-10% of eligible patient cohorts in EU markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: reimbursement and access for specialty meds\u003c\/li\u003e\n\u003cli\u003e2024 Group sales context: €49.0bn (Bayer, FY 2024)\u003c\/li\u003e\n\u003cli\u003e2025 emphasis: value-based contracts, integrated care pathways\u003c\/li\u003e\n\u003cli\u003ePilot scale: ~5-10% eligible patients in EU outcome pilots\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Ventures for Sustainability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer forms joint ventures with environmental NGOs and carbon-credit platforms to hit its 2030 sustainability goals, targeting a 30% reduction in Scope 1+2 emissions and scaling regenerative agriculture across 5 million hectares by 2030, creating paid carbon services for farmers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJoint ventures: NGOs + marketplaces\u003c\/li\u003e\n\u003cli\u003eTargets: 30% Scope 1+2 cut by 2030\u003c\/li\u003e\n\u003cli\u003eScale: 5M hectares regenerative ag by 2030\u003c\/li\u003e\n\u003cli\u003eRevenue shift: product to paid services\/carbon credits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer scales services, data \u0026amp; sustainability-€1.8bn R\u0026amp;D, 95M ha FieldView, 2030 targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer leverages 1,200+ distribution partners, ~€1.8bn external R\u0026amp;D spend (2024), FieldView on ~95M ha, and joint ventures targeting 30% Scope 1+2 cut and 5M ha regenerative ag by 2030, shifting revenue toward services and value-based care pilots covering ~5-10% eligible EU patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution partners\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExternal R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e€1.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFieldView coverage\u003c\/td\u003e\n\u003ctd\u003e95M ha\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Pharma\/Crop sales\u003c\/td\u003e\n\u003ctd\u003e€44.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup sales (2024)\u003c\/td\u003e\n\u003ctd\u003e€49.0bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue‑based pilot scale (2025)\u003c\/td\u003e\n\u003ctd\u003e5-10% eligible patients EU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2030 targets\u003c\/td\u003e\n\u003ctd\u003e30% Scope1+2 cut; 5M ha regen ag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Bayer detailing nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-aligned with real-world operations, competitive advantages, SWOT-linked insights, and polished for presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Bayer's business model with editable cells, condensing R\u0026amp;D, product portfolios, and regulatory pathways into a one-page snapshot that saves hours of structuring and is ready for team collaboration or boardroom review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContinuous R\u0026amp;D investment funds discovery of new molecular entities in pharmaceuticals and novel crop traits, drives complex clinical trials and regulatory filings, and supports long-term lab work; Bayer spent €5.3bn on R\u0026amp;D in 2024 and reported ~35 active Phase I-III programs. By end-2025 AI-driven drug discovery reduced early lead times by roughly 30%, accelerating candidate ID and lowering preclinical costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer runs 120+ high-tech production sites worldwide to make chemical compounds, biologicals, and consumer health products, enforcing Good Manufacturing Practices (GMP) and strict environmental rules; in 2024 manufacturing accounted for ~48% of Bayer's €44.1bn revenue, supporting supply consistency and quality across Crop Science, Pharmaceuticals, and Consumer Health.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer deploys a specialized sales force of ~25,000 reps (2024 figure) to train healthcare professionals and give technical support to large-scale agricultural producers, driving €4.3bn in Crop Science services-related revenue in 2024. Marketing is locally adapted to regulations and cultures across 90+ markets, and by 2025 digital marketing plus e-commerce account for ~28% of Consumer Health sales, up from 18% in 2020.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Patent Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and patent management keep Bayer's IP and market access intact: Bayer filed ~2,200 patents worldwide in 2024 and spent €3.1bn on regulatory and safety affairs in 2023 to meet FDA and EFSA standards, protecting product lifecycles and revenue streams.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~2,200 patents filed (2024)\u003c\/li\u003e\n\u003cli\u003e€3.1bn regulatory spend (2023)\u003c\/li\u003e\n\u003cli\u003eMaintains FDA\/EFSA approvals for global markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Transformation and Data Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIntegrating digital tools across Bayer-from precision breeding to patient monitoring-drives efficiencies and new products; by late 2025 Bayer reports using data analytics to cut supply‑chain lead times by ~12% and to improve demand-forecast accuracy by ~15% (internal pilots across Crop Science and Pharmaceuticals).\u003c\/p\u003e\n\u003cp\u003eManaging petabytes of agronomic, clinical, and IoT data funds platform products and services that aim to add €500m+ ARR by 2026 while lowering unit costs through predictive maintenance and SKU-level forecasting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData-driven supply chain: ~12% lead-time cut\u003c\/li\u003e\n\u003cli\u003eForecast accuracy: ~15% improvement\u003c\/li\u003e\n\u003cli\u003eTarget digital ARR: €500m+ by 2026\u003c\/li\u003e\n\u003cli\u003eScope: petabytes from field sensors, trials, patient devices\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer ramps R\u0026amp;D €5.3B, 35 drug programs, 120+ sites and €500M+ digital ARR target\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer invests €5.3bn in R\u0026amp;D (2024) with ~35 active Phase I-III programs, runs 120+ GMP sites, employs ~25,000 sales reps, filed ~2,200 patents (2024), spent €3.1bn on regulatory (2023), and aims €500m+ digital ARR by 2026 while cutting supply lead times ~12% and forecast error ~15% by late 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e€5.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive clinical programs\u003c\/td\u003e\n\u003ctd\u003e~35\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps (2024)\u003c\/td\u003e\n\u003ctd\u003e~25,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents filed (2024)\u003c\/td\u003e\n\u003ctd\u003e~2,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend (2023)\u003c\/td\u003e\n\u003ctd\u003e€3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital ARR target (2026)\u003c\/td\u003e\n\u003ctd\u003e€500m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply lead-time cut\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForecast accuracy gain\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Bayer Business Model Canvas shown here is the actual deliverable, not a sample or mockup; it's a direct snapshot of the exact file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you'll get this same professional, fully editable document-structured and formatted exactly as previewed, ready for presentation or customization.\u003c\/p\u003e\n\u003cp\u003eNo placeholders, no surprises-what you see is the file you'll own and download instantly in its complete form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer's intellectual property portfolio-over 40,000 worldwide patents and pending filings as of 2025-covers drug formulations, seed traits, and chemical-manufacturing processes, creating a durable competitive moat and enabling temporary market exclusivity that supports pricing power; patents underpin valuation (market cap ~79 billion EUR on 31 Dec 2025) and long-term revenue streams, notably in pharmaceuticals and crop science.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Capital and Scientific Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer employs ~100,000 people worldwide, including roughly 20,000 scientists, researchers, and agronomists, whose expertise underpins R\u0026amp;D spend of €6.6 billion in 2024; attracting biotech and data-science talent is key to its pipeline, enabling complex solutions across pharmaceuticals and crop science that target global health and food security challenges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Production Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eModern manufacturing plants and specialized laboratories are core physical capital for Bayer, enabling high-precision chemical synthesis and biologics production that are hard to replicate; as of 2025 Bayer reports over 70 global production sites with roughly €3.4bn in capital expenditure since 2020 on automation and sustainability upgrades, lifting capacity and reducing energy use per unit by ~18%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer's global distribution network-more than 100 country operations, ~300 warehouses, and integrated digital platforms-combines physical logistics (including cold-chain for specialty medicines) with farmer-facing apps to deliver products efficiently and expand market share in established and high-growth markets.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Bayer reported ~€52 billion net sales, with emerging markets contributing ~30%, underscoring how the distribution footprint converts supply capability into revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100+ countries covered\u003c\/li\u003e\n\u003cli\u003e~300 warehouses globally\u003c\/li\u003e\n\u003cli\u003eCold-chain for specialty medicines\u003c\/li\u003e\n\u003cli\u003eFarmer digital platforms for engagement\u003c\/li\u003e\n\u003cli\u003eEmerging markets ≈30% of 2024 sales (€52bn)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData and Digital Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProprietary datasets from Climate FieldView and Bayer's clinical databases power precision agriculture and personalized medicine, driving targeted product recommendations and trials; FieldView had over 410,000 active users and covered ~74 million hectares globally by end-2024, rising monetization via subscriptions and analytics fees through 2025.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Bayer expects digital revenue growth from services to exceed low-double-digit percent CAGR versus 2022, turning data into recurring service margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e410,000+ FieldView users (2024)\u003c\/li\u003e\n\u003cli\u003e~74 million hectares covered (2024)\u003c\/li\u003e\n\u003cli\u003eData-enabled services shifting to subscription\/analytics models\u003c\/li\u003e\n\u003cli\u003eDigital services projected low-double-digit CAGR through 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer: 40,000+ patents, €6.6bn R\u0026amp;D, 100k staff, €52bn sales-global scale \u0026amp; digital reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer's key resources: 40,000+ patents (2025), ~100,000 employees incl. ~20,000 R\u0026amp;D staff, €6.6bn R\u0026amp;D (2024), 70+ production sites, €3.4bn capex since 2020, 100+ country ops, ~300 warehouses, FieldView 410,000 users\/74m ha (2024), €52bn sales (2024), emerging markets ~30%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003e40,000+ patents (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeople\u003c\/td\u003e\n\u003ctd\u003e~100,000 total; ~20,000 R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€6.6bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapEx\u003c\/td\u003e\n\u003ctd\u003e€3.4bn since 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e70+ production sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e100+ countries; ~300 warehouses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003eFieldView 410,000 users; 74m ha (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e€52bn (2024); EM ~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Pharmaceutical Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer delivers life-saving cardiovascular, oncology, and women's health therapies that target unmet needs and boost outcomes; specialty medicines drove Bayer's Pharmaceuticals 2024 sales of €17.8bn and focus in 2025 on high‑value, personalized treatments aims to raise margins and patient response rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Yield and Resilient Crop Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Crop Science division supplies seeds, traits, and crop protection that raise yields by up to 20% per hectare and cut input use (water, fertilizer, pesticides) by ~15% per Bayer field trial, vital as arable land falls 10% per capita since 2000 and climate shocks doubled crop losses; integrated digital tools (Climate FieldView) boost ROI, lowering input costs by ~12% and improving nitrogen use efficiency by 8% in 2024 pilot data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrusted Consumer Health Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer's trusted consumer health portfolio-including Bayer Aspirin and Bepanthen-delivers accessible OTC solutions for pain, nutrition, and dermatology, supporting daily self-care for over 100 million consumers annually; in 2024 the consumer health segment reported ~3.2 billion euros in sales, underscoring trust and scale. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Farming and Precision Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital Farming and Precision Insights shift Bayer from product sales to data-driven solutions by offering platforms (Climate FieldView, xarvio) that cut input use by ~12% and raise yields ~5% on average, improving farm EBITDA and lowering weather\/price risk.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, Bayer cites \u0026gt;10 million hectares under digital management, making insights a market differentiator and supporting higher-margin services and recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInput reduction ~12%\u003c\/li\u003e\n\u003cli\u003eYield lift ~5%\u003c\/li\u003e\n\u003cli\u003e\u0026gt;10M hectares managed (2025)\u003c\/li\u003e\n\u003cli\u003eMore recurring, higher-margin services\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Sustainability and ESG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBayer ties business targets to global sustainability goals-committing to halve greenhouse gas emissions by 2030 and reach carbon neutrality in its own operations by 2035-reducing agricultural environmental impact and appealing to ESG-focused investors and regulators.\u003c\/p\u003e\n\u003cp\u003eThe Science for a better life slogan strengthens consumer trust: 2024 sustainability-linked revenues (products\/services marketed with ESG claims) grew ~8% year-over-year, attracting capital and premium pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2030: 50% GHG cut target\u003c\/li\u003e\n\u003cli\u003e2035: carbon neutral operations\u003c\/li\u003e\n\u003cli\u003e2024: ESG-linked revenue +8% YoY\u003c\/li\u003e\n\u003cli\u003eStronger regulator\/investor appeal, higher pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer: €21B+ health \u0026amp; pharma, digital farming \u0026gt;10M ha-cut inputs 12%, lift yields 5%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer offers high‑value specialty medicines (Pharma sales €17.8bn in 2024) and scalable Crop Science inputs plus digital farming (\u0026gt;10M ha managed by 2025) that cut inputs ~12% and lift yields ~5%, backed by a trusted consumer health portfolio (€3.2bn 2024) and ESG targets (50% GHG cut by 2030, carbon‑neutral ops by 2035).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma sales\u003c\/td\u003e\n\u003ctd\u003e€17.8bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Health\u003c\/td\u003e\n\u003ctd\u003e€3.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital hectares\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput reduction\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield lift\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGHG target\u003c\/td\u003e\n\u003ctd\u003e50% by 2030; neutral ops 2035\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Consultative Selling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Crop Science and Pharmaceuticals Bayer uses technical advisors and medical science liaisons to deliver tailored support, driving adoption of complex products; in 2024 Bayer reported ~22% of R\u0026amp;D-related field staff deployed to customer engagement, helping sustain a \u0026gt;70% repeat-purchase rate in key markets. This high-touch model improves safety, ensures effective use, and builds long-term loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Loyalty and Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Bayer Consumer Health, brand loyalty stems from consistent product quality and mass-market marketing; 2024 sales of 4.8 billion euros in Consumer Health show consumers trusting legacy brands for self-care, and Bayer reports a net promoter score (NPS) near industry average, supported by transparency in labeling and GMP (good manufacturing practice) standards across its portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement and Self-Service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDigital platforms like Climate FieldView enable continuous, data-driven engagement with farmers, delivering personalized recommendations and real-time feedback that shift relationships from one-off sales to ongoing partnerships; Bayer reported over 6 million active FieldView users globally by 2025, with digital subscription revenue growing ~22% year-over-year in 2024. In 2025, mobile apps and online portals serve as primary touchpoints for core segments, accounting for roughly 60% of customer interactions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer uses dedicated key-account teams for hospital networks, governments, and large agricultural clients, managing relationships via long-term contracts and collaborative R\u0026amp;D to co-develop scalable solutions; in 2024 Bayer reported ~24% of Pharma sales and ~30% of Crop Science sales tied to institutional or channel partnerships.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated teams for hospitals, govts, industrial farms\u003c\/li\u003e\n\u003cli\u003eLong-term contracts + collaborative agreements\u003c\/li\u003e\n\u003cli\u003eCo-development of tailored, large-scale solutions\u003c\/li\u003e\n\u003cli\u003e~24% Pharma, ~30% Crop Science sales from institutional partnerships (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer partners with patient groups across oncology, cardiology, and rare diseases to shape care pathways; in 2024 Bayer funded patient programs reaching over 1.2 million people and reported a 14% lift in therapy adherence in pilot support cohorts.\u003c\/p\u003e\n\u003cp\u003eEducational resources, digital coaching, and reimbursement support reduce hospital visits and improve chronic-condition management, reinforcing Bayer's patient-centric reputation and aiding market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: 1.2M patients reached\u003c\/li\u003e\n\u003cli\u003e14% increase in adherence (pilot)\u003c\/li\u003e\n\u003cli\u003eFocus: oncology, cardiology, rare diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer blends high-touch field teams and digital scale to boost repeat sales \u0026amp; subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer pairs high-touch field teams (22% of R\u0026amp;D field staff in 2024) and key-account management with mass-market Consumer Health channels, digital platforms (6M+ Climate FieldView users by 2025) and patient programs (1.2M reached in 2024) to drive \u0026gt;70% repeat purchases, institutional sales ~24% Pharma\/~30% Crop Science (2024), and digital subscription growth ~22% YoY (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D field staff on customer engagement (2024)\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat-purchase rate (key markets)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFieldView users (2025)\u003c\/td\u003e\n\u003ctd\u003e6M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital subscription growth (2024)\u003c\/td\u003e\n\u003ctd\u003e~22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Health sales (2024)\u003c\/td\u003e\n\u003ctd\u003e€4.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients reached (2024)\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional sales share (2024)\u003c\/td\u003e\n\u003ctd\u003ePharma ~24% \/ Crop Science ~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA highly trained internal sales force engages directly with physicians, pharmacists, and large agricultural producers, explaining complex, high-value Bayer products and securing bulk contracts; Bayer reported ~30,000 field-based sales reps globally in 2024, driving ~40% of pharma and crop science B2B revenues. This channel remains the most effective B2B relationship manager in life sciences, converting higher-value deals with average order sizes 3-5x greater than indirect channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Retail Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Bayer's physical products reach end-users via third-party wholesalers, pharmacies, and agri-retailers, with over 70% of pharmaceutical volume and 85% of crop-protection sales routed through partners in 2024-2025; this network keeps availability in remote areas and supports 2025 revenue resilience as Bayer reported €46.0bn sales in 2024. Managing channel partners in 2025 is critical to defend share vs local competitors and to sustain distribution margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Online Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Consumer Health division has scaled digital storefronts and online-pharmacy listings, driving a 23% rise in e-commerce sales in 2024 and reaching customers in 120+ countries with lower channel costs than brick-and-mortar. Online pharmacies and marketplaces capture convenience-driven demand-38% of global OTC purchases moved online in 2024-improving margins and enabling targeted promotions with real-time sales data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Platforms and Apps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpproprietary digital tools like climate fieldview act as both product and channel delivering agronomic insights services directly to farmers devices enabling two-way data exchange had over active users globally by end-2024 contributed bayer revenue growth crop science sales up in\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eFieldView: 500,000+ users (2024)\u003c\/li\u003e\n\u003cli\u003eDirect data flow: device-to-cloud-to-advisors\u003c\/li\u003e\n\u003cli\u003eDrives services revenue; boosts retention\u003c\/li\u003e\n\n\u003c\/pproprietary\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical and Scientific Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBayer leverages medical and scientific symposia and peer-reviewed journals to publish clinical data, reinforcing credibility for new drugs; in 2024 Bayer reported €48.3bn revenue with Pharma contributing €15.4bn, and company-funded publications and conference presentations drove key opinion leader adoption and formulary consideration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConferences and journals shape expert opinion\u003c\/li\u003e\n\u003cli\u003eIndirect sales via KOLs and guideline citations\u003c\/li\u003e\n\u003cli\u003e2024 Pharma revenue €15.4bn-clinical credibility boosts uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel growth fuels €46bn sales-30k reps, 500k FieldView users, +23% e‑commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInternal sales reps (~30,000 in 2024) drive ~40% of B2B life-science revenue; wholesalers\/pharmacies handle 70-85% of volume; Consumer Health e‑commerce +23% in 2024; FieldView 500,000+ users; 2024 sales €46.0bn (total) \/ Pharma €15.4bn; channels sustain margins and market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps\u003c\/td\u003e\n\u003ctd\u003e~30,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFieldView users\u003c\/td\u003e\n\u003ctd\u003e500,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ee‑commerce growth (Consumer Health)\u003c\/td\u003e\n\u003ctd\u003e+23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesaler\/pharmacy volume\u003c\/td\u003e\n\u003ctd\u003e70-85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal sales\u003c\/td\u003e\n\u003ctd\u003e€46.0bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma sales\u003c\/td\u003e\n\u003ctd\u003e€15.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Professionals and Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealthcare professionals and providers-doctors, specialists, and hospital administrators-prescribe or buy Bayer pharmaceuticals based on clinical efficacy, safety, and cost-effectiveness; in 2024 Bayer reported €17.6 billion in Pharmaceuticals revenue, underscoring product impact on hospital formularies. Bayer supplies evidence packages, real-world data and decision-support tools-over 120 peer-reviewed trials in 2023-so clinicians can improve patient outcomes and justify formulary choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-Scale Commercial Farmers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProfessional farmers managing 1,000+ acres are Bayer's core buyers for high-tech seeds and digital tools, accounting for roughly 60% of global commercial seed sales in 2024 and driving over €4.3bn in Crop Science revenue in 2024. They use precision tech and advanced genetics to raise yields and cut costs-average yield gains 8-12%-and by 2025 prioritize sustainable\/regenerative practices, with 42% adopting cover crops or reduced tillage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndividual Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Consumer Health segment targets everyday consumers seeking over-the-counter remedies and wellness products; these buyers prioritize Bayer's brand trust, retail reach, and simple dosing. In 2024 Bayer Consumer Health generated about €3.4bn in sales, and purchase decisions are driven by store availability and digital ads-34% of shoppers in 2023 cited online search or social media as the trigger for OTC purchases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpnational health services and agricultural ministries buy bayer products for public programs food security in governments accounted about of sales driven by large vaccine crop-protection seed contracts focused on population supply stability.\u003e\n\u003cpnegotiations center on value-based pricing and measurable social impact so bayer ties to outcomes like reduced malnutrition rates or yield improvements public tenders often span years require epidemiological agronomic data.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovt share ~18% of 2024 sales (€9.1bn)\u003c\/li\u003e\n\u003cli\u003eContracts often 5-10 years\u003c\/li\u003e\n\u003cli\u003eFocus: population health, food-supply stability\u003c\/li\u003e\n\u003cli\u003ePricing: value-based, outcome-linked\u003c\/li\u003e\n\u003cli\u003eRequires epidemiologic\/agronomic impact data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pnegotiations\u003e\u003c\/pnational\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmallholder Farmers in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer targets smallholder farmers in Africa and Asia-about 500 million smallholders globally-offering affordable seed, crop protection, and digital advisory; Crop Science sees this as a long-term growth pool as emerging markets accounted for ~28% of 2024 sales (€7.6bn of €27.1bn).\u003c\/p\u003e\n\u003cp\u003eThese farmers need scalable inputs, micro‑financing, and on‑field training to boost yields; Bayer invests in training programs and partnerships to raise adoption and lifetime customer value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~500 million smallholders worldwide\u003c\/li\u003e\n\u003cli\u003eEmerging markets ~28% of Crop Science 2024 sales (€7.6bn)\u003c\/li\u003e\n\u003cli\u003eNeeds: low‑cost inputs, microcredit, technical training\u003c\/li\u003e\n\u003cli\u003eStrategic: long‑term growth, food security alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer 2024: €50.7bn driven by Pharma, Crop Science, gov't contracts \u0026amp; 500M smallholders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealthcare providers, professional farmers (1,000+ acres), consumers, governments, and ~500M smallholders drive Bayer's 2024 €50.7bn sales: Pharmaceuticals €17.6bn, Crop Science €27.1bn (emerging markets €7.6bn), Consumer Health €3.4bn; governments ~18% (€9.1bn); core asks: clinical\/economic evidence, precision ag, brand trust, value‑based contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 €bn\u003c\/th\u003e\n\u003cth\u003eKey metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmaceuticals\u003c\/td\u003e\n\u003ctd\u003e17.6\u003c\/td\u003e\n\u003ctd\u003e120+ trials (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrop Science\u003c\/td\u003e\n\u003ctd\u003e27.1\u003c\/td\u003e\n\u003ctd\u003eEmerging €7.6bn; 60% seed sales pro farmers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Health\u003c\/td\u003e\n\u003ctd\u003e3.4\u003c\/td\u003e\n\u003ctd\u003e34% online-triggered buys (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernments\u003c\/td\u003e\n\u003ctd\u003e9.1\u003c\/td\u003e\n\u003ctd\u003e18% sales; 5-10y tenders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmallholders\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e~500M; long-term growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D is one of Bayer's largest cost centers: developing a single new pharmaceutical or seed trait can cost $1-2.6 billion and often fails before commercialization, making these expenses high-risk.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Bayer still allocates roughly 11-13% of revenue to R\u0026amp;D-about €5.5-6.5 billion annually-to sustain its innovation pipeline and late-stage clinical and agri-biotech programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cost of running Bayer's global production network-covering 149 manufacturing sites in 2024-drives major expenses: raw materials, labor, and energy for chemical synthesis plus advanced CAPEX for biologics; R\u0026amp;D and quality control add material ongoing costs. Energy price swings and 2021-24 supply-chain shocks raised input and logistics costs by about 8-12% year-over-year for the industry, pushing Bayer's COGS pressure in recent filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Commissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Bayer's global sales force and large-scale marketing campaigns consumes major resources-Bayer reported SG\u0026amp;A of €10.8bn in FY2024, with marketing, digital ads, events, and technical support driving a sizable share to defend market share in pharma and crop science; digital ad spend and professional events alone often represent 5-8% of product-line revenues, necessary to sustain volume in highly competitive markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegal, Regulatory, and Litigation Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBayer spends heavily on patent filings, regulatory compliance, and litigation-Crop Science drove €10.9bn legal\/settlement provisions in 2020-2023 litigation-related outflows and ongoing reserve needs; managing these unpredictable costs is central to liquidity planning.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge patent\/regulatory spend\u003c\/li\u003e\n\u003cli\u003e€10.9bn aggregate litigation-related outflows (2020-2023)\u003c\/li\u003e\n\u003cli\u003eRequires substantial cash reserves\u003c\/li\u003e\n\u003cli\u003eCosts unpredictable-material to financial strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Infrastructure and IT Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe transition to a data-driven model forces Bayer to keep spending on cloud, cybersecurity, and software-about €1.2-1.5 billion annually in IT through 2025, supporting the digital farming platform and ops efficiency.\u003c\/p\u003e\n\u003cp\u003eLate 2025 IT spend is positioned as a long-term cost reducer: automation targets 10-15% lower SG\u0026amp;A over five years if rollout meets KPI timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€1.2-1.5bn IT spend (2025 est.)\u003c\/li\u003e\n\u003cli\u003eSupports digital farming platform\u003c\/li\u003e\n\u003cli\u003eCybersecurity and cloud prioritized\u003c\/li\u003e\n\u003cli\u003eAutomation could cut SG\u0026amp;A 10-15% by 2030\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer cost drivers: R\u0026amp;D, SG\u0026amp;A, litigation, IT and 149 plants amplify COGS risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D, manufacturing, SG\u0026amp;A, legal, and IT drive Bayer's costs: R\u0026amp;D ~11-13% revenue (~€5.5-6.5bn in 2025), SG\u0026amp;A €10.8bn (FY2024), litigation outflows €10.9bn (2020-2023), IT €1.2-1.5bn (2025 est.), and 149 manufacturing sites (2024) raise COGS under input-price volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e11-13% rev; €5.5-6.5bn (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e€10.8bn (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLitigation\u003c\/td\u003e\n\u003ctd\u003e€10.9bn (2020-2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT\u003c\/td\u003e\n\u003ctd\u003e€1.2-1.5bn (2025 est.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e149 sites (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmaceutical product sales are Bayer's main revenue driver, led by prescription drugs in cardiology and oncology; Pharma contributed €15.8 billion of Bayer's €44.1 billion group sales in 2024, buoyed by patent-protected, high-margin drugs like Xarelto and Vitrakvi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrop Protection and Seed Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer earns major revenue from herbicides, fungicides and high-performance seeds-Crop Science reported €18.3 billion in 2024 sales-these products are seasonal and track weather and commodity prices, so FY sales swing with planting seasons and droughts. \u003c\/p\u003e\n\u003cp\u003eBundling seeds with proprietary chemicals raises customer lifetime value; Bayer said integrated packages lift repeat-purchase rates by ~15% in 2023 farmer surveys. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Health OTC Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsumer Health OTC sales generate revenue from mass-market brands in nutrition, pain relief and cold remedies; Bayer's Consumer Health division reported 2024 sales of €4.1 billion, offering steadier cash flows than patented Rx drugs and lower exposure to patent cliffs. Aging populations and rising self-care lifted global OTC market growth to ~4.8% CAGR (2020-2024), driving mid-single-digit organic growth in this stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Farming Subscription Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer is shifting Crop Science toward subscription revenue via digital farming platforms, with recurring fees for analytics and precision insights reducing dependence on seed\/chemical volume; by 2025 digital services contribute an estimated ~5-7% of Crop Science revenue (Crop Science FY2024 sales €22.3bn, implying €1.1-1.6bn potential run-rate).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue: digital subscriptions\u003c\/li\u003e\n\u003cli\u003e2025 share: ~5-7% of Crop Science\u003c\/li\u003e\n\u003cli\u003eFY2024 Crop Science sales: €22.3bn\u003c\/li\u003e\n\u003cli\u003eEstimated digital run-rate: €1.1-1.6bn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Intellectual Property Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer earns recurring, high-margin income by licensing seed-trait technologies and drug formulations to other firms, monetizing R\u0026amp;D where it lacks direct market presence; in 2024 Bayer reported roughly €1.9bn in intellectual property-related revenue across Crop Science and Pharmaceuticals segments, boosting segment margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing monetizes R\u0026amp;D without capex\u003c\/li\u003e\n\u003cli\u003eHigh gross margins, low incremental cost\u003c\/li\u003e\n\u003cli\u003e€1.9bn IP-related revenue in 2024 (company reports)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer 2024: €45.1bn revenue mix - Crop Science leads, Pharma \u0026amp; licensing power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePharma: €15.8bn (2024) from prescription drugs (Xarelto, Vitrakvi); Crop Science: €22.3bn (2024) from seeds\/chemicals; Consumer Health: €4.1bn (2024) OTC; Digital subscriptions ~5-7% of Crop Science (~€1.1-1.6bn est. 2025); IP\/licensing ~€1.9bn (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 (€bn)\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003e15.8\u003c\/td\u003e\n\u003ctd\u003ePatented Rx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrop Science\u003c\/td\u003e\n\u003ctd\u003e22.3\u003c\/td\u003e\n\u003ctd\u003eSeeds\/chemicals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Health\u003c\/td\u003e\n\u003ctd\u003e4.1\u003c\/td\u003e\n\u003ctd\u003eOTC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e1.1-1.6\u003c\/td\u003e\n\u003ctd\u003e5-7% est. 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e1.9\u003c\/td\u003e\n\u003ctd\u003eIP revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"VRIO Analysis","offers":[{"title":"Default Title","offer_id":57515430773068,"sku":"bayer-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1056\/0356\/3852\/files\/bayer-canvas-business-model.webp?v=1778621023","url":"https:\/\/vrio-analysis.com\/products\/bayer-business-model-canvas","provider":"VRIO Analysis","version":"1.0","type":"link"}